Objective: To investigate the attitudes and actions of patients with chronic obstructive pulmonary disease (COPD) on treatment.
Methods: A nation-wide multi-center, questionnaire study was carried out to investigate the patient understanding and experience of COPD treatment between Sep. 2007 and Dec. 2008. The questionnaire included the patients' understanding of goal of COPD treatment, previous treatment, and expectation on drugs. The data were analyzed by descriptive statistical methods.
Results: 2072 patients with COPD in 11 centers were interviewed in the study. The final effective questionnaires were collected from 1698 cases. 653 patients had known of COPD. The attitudes and actions on treatment were analyzed based on these patients. The patients had different understanding of goals for COPD treatment, including 59.1% (384/650) for relieving symptoms. In recent 3 months, the most commonly used drugs were theophylline (53.7%, 351/653), iprotropium (39.8%, 260/653), tiotropium (27.1%, 177/653). 72.0% (465/646) patients used the drugs according to the prescriptions. There were more than 80% patients who did not understand the side effects of anti-cholinergics, β-adrenergic agonists, inhaled steroids, inhaled steroid/long-acting β-agonist combination therapy, or theophyllines. 37.4% (240/641) patients were afraid of side effects of inhaled steroids. 42.2% (274/650) patients often took antibiotics. There was no oxygen supply at home in 60.1% (391/651) patients. 70.5% (457/648) did not have pulmonary rehabilitation. Requirement of long-term regular treatment was considered in 77.4% (500/646) patients. The most important thing about patients' attitude on ideal drugs for COPD was drug efficacy (79.6%, 481/604). The most ideal drug used in the past was fluticasone/salmeterol or tiotropium (16.9%, 78/461).
Conclusions: Patients had different attitudes and actions on COPD treatment. Patient education should be strengthened to realize treatment goals for COPD.
Download full-text PDF |
Source |
---|
Respir Res
January 2025
Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Center for Chronic Disease Prevention and Control, Harbin Medical University, Harbin, 150081, People's Republic of China.
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, influenced by both environmental and genetic factors. Single nucleotide polymorphism (SNP) in the human genome may influence the risk of developing COPD and the response to treatment. We assessed the effects of gene polymorphism of inflammatory and immune-active factors and gene-environment interaction on risk of COPD in middle-aged and older Chinese individuals.
View Article and Find Full Text PDFBMC Med Genomics
January 2025
Administrative Office, The Fourth People's Hospital of Nanning, Nanning, China.
Background: Chronic obstructive pulmonary disease (COPD) is a chronic and progressive lung disease. Disulfidptosis-related genes (DRGs) may be involved in the pathogenesis of COPD. From the perspective of predictive, preventive, and personalized medicine (PPPM), clarifying the role of disulfidptosis in the development of COPD could provide a opportunity for primary prediction, targeted prevention, and personalized treatment of the disease.
View Article and Find Full Text PDFRespir Res
January 2025
Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Banacha 1a, Warsaw, 02-097, Poland.
Background: Pathobiology of asthma and chronic obstructive pulmonary disease (COPD) is associated with changes among respiratory epithelium structure and function. Increased levels of PM from urban particulate matter (UPM) are correlated with enlarged rate of asthma and COPD morbidity as well as acute disease exacerbation. It has been suggested that pre-existing pulmonary obstructive diseases predispose epithelium for different biological response than in healthy airways.
View Article and Find Full Text PDFKorean J Intern Med
January 2025
Department of Respiratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Background/aims: Chronic obstructive pulmonary disease (COPD) management guidelines have increasingly emphasised the importance of exacerbation prevention, and the role of blood eosinophil count (BEC) as a biomarker for inhaled corticosteroids (ICS) response. This study aimed to describe the distribution and stability of BEC and understand real-world treatment patterns among COPD patients in South Korea.
Methods: This was a retrospective database analysis using data obtained from the KOrea COPD Subgroup Study (KOCOSS) registry between January 2012 and August 2018.
Korean J Intern Med
January 2025
Division of Respiratory and Critical Care, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!